Transcatheter Aortic Valve Replacement in the Asian Population: What Did We Learn and Not Learn?

  • Alan Yeung
  • Published 2016 in JACC. Cardiovascular interventions


SEE PAGE 926 T ranscatheter aortic valve replacement (TAVR) has entered the main stream of interventional cardiology and cardiac surgery practice in the United States. It offers hitherto clinical benefits unobtainable tomany patientswho are deemed too high risk for traditional cardiac surgery requiring open chest, cardiopulmonary bypass, high level of anticoagulation, and ventricular standstill. The PARTNER (Placement of Aortic Transcatheter Valves) family of trials aswell as the CoreValve U.S. High-Risk trial has offered strong evidence that TAVR resulted in better clinical outcomes in inoperable/extreme risk patients than medical therapy. In high-risk patients, TAVR offers equivalent if not better clinical outcomes (1,2). Continue access data has also shown that the clinical outcomes continue to improve as devices size reduced further and the team experience accumulated over time (3). Furthermore, the U.S. TVT (Transcatheter Valve Therapy) registry has been set up as a mandated post-market registry that track the clinical characteristics as well as outcome for all patients undergoing TAVR for 1 year (4). Results of the PARTNER IIA trial, which is a randomized study of TAVR versus open aortic valve surgery in intermediate risk patients, will have been presented at the American College of Cardiology 2016 by the time this issue is published. It will likely show that TAVR in intermediate risk patients will be noninferior to open surgery, confirming the result from a propensity matched dataset (5). Aortic stenosis

DOI: 10.1016/j.jcin.2016.03.007

Cite this paper

@article{Yeung2016TranscatheterAV, title={Transcatheter Aortic Valve Replacement in the Asian Population: What Did We Learn and Not Learn?}, author={Alan Yeung}, journal={JACC. Cardiovascular interventions}, year={2016}, volume={9 9}, pages={934-6} }